Carsten Schröder1, Michael Dörks2, Bianca Kollhorst3, Tilo Blenk1, Ralf W Dittmann4, Edeltraut Garbe1, Oliver Riedel1. 1. Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. 2. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany. 3. Department of Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. 4. Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Abstract
PURPOSE: Recent studies on the utilization of antidepressant drugs in minors are scarce, methodologically limited, and do not factor in off-label use sufficiently. Beyond that, little is known about the short treatment durations that have been observed for many young antidepressant users. The present study examined antidepressant use in pediatric patients aged 0 to 17 years over time, investigated changes regarding the prescribed drugs, analyzed underlying diagnoses, and assessed the rate of off-label use. METHODS: We used claims data of roughly two million individuals to calculate annual prevalence and incidence rates of antidepressant prescriptions for the years 2004 to 2011. Analyses were stratified by age, sex, and drug type. For antidepressant users, numbers of prescriptions, frequencies of disorders/diseases, and specialties of the prescribing physicians were examined. The share of off-label prescriptions was calculated for each year. RESULTS: The prescription prevalence of antidepressants ranged between 1.7 and 2.1 per 1000 minors. The use of tricyclic antidepressants decreased from 0.9 to 0.6 prescriptions per 1000 minors, while the use of selective serotonin reuptake inhibitors increased from 0.5 to 1.1. Of the patients with an antidepressant prescription, 46.4% only received one prescription. Depression was by far the most frequent diagnosis among all antidepressant users as well as among subjects with only one prescription. In 2011, 36.3% of all prescriptions were off-label. CONCLUSIONS: The high proportion of single prescriptions, even in patients with a diagnosed depression, and the high rate of off-label use are particularly noteworthy and should be further investigated in future studies.
PURPOSE: Recent studies on the utilization of antidepressant drugs in minors are scarce, methodologically limited, and do not factor in off-label use sufficiently. Beyond that, little is known about the short treatment durations that have been observed for many young antidepressant users. The present study examined antidepressant use in pediatric patients aged 0 to 17 years over time, investigated changes regarding the prescribed drugs, analyzed underlying diagnoses, and assessed the rate of off-label use. METHODS: We used claims data of roughly two million individuals to calculate annual prevalence and incidence rates of antidepressant prescriptions for the years 2004 to 2011. Analyses were stratified by age, sex, and drug type. For antidepressant users, numbers of prescriptions, frequencies of disorders/diseases, and specialties of the prescribing physicians were examined. The share of off-label prescriptions was calculated for each year. RESULTS: The prescription prevalence of antidepressants ranged between 1.7 and 2.1 per 1000 minors. The use of tricyclic antidepressants decreased from 0.9 to 0.6 prescriptions per 1000 minors, while the use of selective serotonin reuptake inhibitors increased from 0.5 to 1.1. Of the patients with an antidepressant prescription, 46.4% only received one prescription. Depression was by far the most frequent diagnosis among all antidepressant users as well as among subjects with only one prescription. In 2011, 36.3% of all prescriptions were off-label. CONCLUSIONS: The high proportion of single prescriptions, even in patients with a diagnosed depression, and the high rate of off-label use are particularly noteworthy and should be further investigated in future studies.
Authors: Francisco J Flores-Ramirez; Lyonna F Parise; Jason B Alipio; Israel Garcia-Carachure; Samuel A Castillo; Minerva Rodriguez; Anapaula Themman; Omar Lira; Joshua Preciado-Piña; Sergio D Iñiguez Journal: J Affect Disord Date: 2019-02-19 Impact factor: 4.839
Authors: Michael Fleming; Catherine A Fitton; Markus F C Steiner; James S McLay; David Clark; Albert King; Daniel F Mackay; Jill P Pell Journal: Int J Epidemiol Date: 2020-08-01 Impact factor: 7.196
Authors: Francisco J Flores-Ramirez; Israel Garcia-Carachure; David O Sanchez; Celene Gonzalez; Samuel A Castillo; Miguel A Arenivar; Anapaula Themann; Omar Lira; Minerva Rodriguez; Joshua Preciado-Piña; Sergio D Iñiguez Journal: J Psychopharmacol Date: 2018-10-18 Impact factor: 4.153
Authors: Divya Hoon; Matthew T Taylor; Pooja Kapadia; Tobias Gerhard; Brian L Strom; Daniel B Horton Journal: Pediatrics Date: 2019-09-16 Impact factor: 7.124
Authors: Michael Fleming; Ehsan E Salim; Daniel F Mackay; Angela Henderson; Deborah Kinnear; David Clark; Albert King; James S McLay; Sally-Ann Cooper; Jill P Pell Journal: PLoS Med Date: 2020-10-13 Impact factor: 11.069
Authors: Michael Fleming; James S McLay; David Clark; Albert King; Daniel F Mackay; Helen Minnis; Jill P Pell Journal: PLoS Med Date: 2021-11-12 Impact factor: 11.069